Traders should monitor for future announcements regarding actual securities offerings, as the shelf registration creates a potential overhang that could pressure the stock if a large offering follows.
Price Chart
Executive Summary
Crescent Biopharma, Inc. has announced the effectiveness of its shelf registration statement (File No. 333-292600), allowing the company to sell securities from time to time. This is not an IPO but a shelf offering, meaning the company may issue shares in the future under current market conditions.
Key Facts
- The SEC has declared effective a shelf registration statement (File No. 333-292600) for Crescent Biopharma, Inc.
- The effectiveness date was March 3, 2026, with the filing accepted on March 4, 2026.
- This is a shelf registration, not an IPO, enabling the company to offer and sell unspecified securities in the future.
- The company was formerly known as Glycomimetics Inc., which changed its name on July 11, 2003.
Financial Impact
Potential future dilution depending on offering size and timing; no immediate financial impact.
Risk Factors
- Future dilution risk if the company issues new shares under the shelf registration.
- Market perception of negative timing if an offering occurs during weak price performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-000704 |
| Document: 9999999995-26-000704-index.html | 9999999995-26-000704 |
| Document: 9999999995-26-000704.txt | 9999999995-26-000704 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $11.84 | awaiting T+60 | awaiting T+60 | $13.27 (+12.08%) |
Oct 15, 2026 12d ago | Press Release | $11.84 | awaiting T+60 | awaiting T+60 | $13.27 (+12.08%) |
Oct 5, 2026 22d ago | Press Release | $13.94 | awaiting T+60 | awaiting T+60 | $13.27 (−4.81%) |
Sep 18, 2026 5w ago | Insider Cluster | $16.25 | awaiting T+60 | awaiting T+60 | $13.27 (−18.34%) |
Jul 30, 2026 12w ago | 8-K | $15.02 $12.82 | ▼ −14.65% | ▼ −17.11% | $13.27 (−11.65%) |
Jul 20, 2026 14w ago | Insider Buy | $16.64 $12.91 | ▼ −22.42% | ▼ −26.39% | $13.27 (−20.25%) |
Jul 15, 2026 14w ago | 8-K / 424B5 | $15.11 $14.91 | ▲ +1.32% | ▲ +5.03% | $13.27 (+12.18%) |
Jul 14, 2026 15w ago | Press Release | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $13.27 (+15.32%) |
Jul 14, 2026 15w ago | 424B5 | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $13.27 (+15.32%) |
Jul 13, 2026 15w ago | EFFECT | $15.69 $13.57 | ▼ −13.51% | ▼ −17.51% | $13.27 (−15.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers